- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
March 17th, 2005
Australian biotech pSivida is looking to boost its profile in the United States as it pushes its new silicon-based drug delivery technology, designed to substantially reduce side-effects in patients.
Speaking at a shareholders briefing in Sydney pSivida managing director Gavin Rezos said shrinking consumer tolerance for drug side effects over the past two decades had made its BioSilicon technology very lucrative.
|Related News Press|
Breaking cell barriers with retractable protein nanoneedles: Adapting a bacterial structure, Wyss Institute researchers develop protein actuators that can mechanically puncture cells February 12th, 2016
Properties of Polymeric Nanofibers Optimized to Treat Damaged Body Tissues February 12th, 2016
SLAC X-ray laser turns crystal imperfections into better images of important biomolecules: New method could remove major obstacles to studying structures of complex biological machines February 11th, 2016
Russia’s Nano-enabled Products Market to Witness Massive Growth February 8th, 2011
Adept Technology Announces Orders for Over $600K from Chinese Partner January 18th, 2011
Nanostart-held ItN Nanovation Receives Major Follow-on Order in Saudi Arabia November 29th, 2010
Homegrown Companies Developing Batteries for Clean Energy Storage November 2nd, 2010